Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jan;114(2):400-4.
doi: 10.1111/j.1476-5381.1995.tb13240.x.

Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein

Affiliations

Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein

E S Ellis et al. Br J Pharmacol. 1995 Jan.

Abstract

1. An 'atypical' 5-HT2 receptor which is located on the endothelium of rat jugular vein has been described. In the present study we have further defined the nature of the 5-HT2 receptor subtype present in this preparation. 2. In experiments conducted in the presence of ketanserin to preclude involvement of 5-HT2 receptors, the mixed 5-HT2B/2C antagonist, SB 200646, acted as an antagonist of 5-HT at the endothelial 5-HT receptor (pA2 = 7.2). Yohimbine, which exhibits negligible affinity for rat 5-HT2C receptors but has high 5-HT2B receptor affinity, acted as a potent but non-surmountable antagonist (pA2 > or = 7.3) in rat jugular vein. Neither yohimbine nor SB 200646 affected endothelium-dependent relaxations induced by carbachol. 3. Mianserin also acted as a surmountable antagonist (pA2 = 7.3) and the 5-HT2B agonist, BW 723C86, acted as a potent partial agonist (pEC50 [95% C L], intrinsic activity +/- s.e. mean = 7.9 [7.6-8.3], 0.84 +/- 0.04). Responses to BW 723C86 were antagonized by SB 200646 (0.3 microM) yielding an 'apparent' pA2 [95% CL] of 7.03 [6.76-7.32]. 4. These data are consistent with the presence of 5-HT2B receptors mediating endothelium-dependent relaxation of rat jugular vein.

PubMed Disclaimer

References

    1. Br J Pharmacol. 1991 Apr;102(4):938-42 - PubMed
    1. J Pharmacol Exp Ther. 1990 Jan;252(1):387-95 - PubMed
    1. FEBS Lett. 1992 Nov 9;312(2-3):203-7 - PubMed
    1. J Pharmacol Exp Ther. 1993 Feb;264(2):709-16 - PubMed
    1. Mol Pharmacol. 1993 Mar;43(3):419-26 - PubMed

MeSH terms

LinkOut - more resources